Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | RecQ helicase-like | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Giardia lamblia | U5 small nuclear ribonucleoprotein 200 kDa helicase, putative | RecQ helicase-like | 649 aa | 521 aa | 19.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 0.3847 | 1 |
Leishmania major | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 0.3847 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Plasmodium vivax | ADP-dependent DNA helicase RecQ, putative | 0.0012 | 0.0146 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Loa Loa (eye worm) | RecQ helicase | 0.0024 | 0.3847 | 1 |
Schistosoma mansoni | DNA helicase recq5 | 0.0024 | 0.3847 | 0.3847 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0024 | 0.3847 | 0.5 |
Entamoeba histolytica | recQ family DNA helicase | 0.0012 | 0.0146 | 0.0146 |
Trypanosoma cruzi | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 0.3847 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Schistosoma mansoni | DNA helicase recq1 | 0.0024 | 0.3847 | 0.3847 |
Entamoeba histolytica | recQ family helicase, putative | 0.0024 | 0.3847 | 0.3847 |
Trichomonas vaginalis | DNA helicase recq1, putative | 0.0024 | 0.3847 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0012 | 0.0146 | 0.0381 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Giardia lamblia | Sgs1 DNA helicase, putative | 0.0024 | 0.3847 | 0.5 |
Schistosoma mansoni | blooms syndrome DNA helicase | 0.0012 | 0.0146 | 0.0146 |
Loa Loa (eye worm) | ATP-dependent DNA helicase | 0.0024 | 0.3847 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Plasmodium falciparum | ATP-dependent DNA helicase Q1 | 0.0024 | 0.3847 | 0.5 |
Trypanosoma brucei | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 0.3847 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.3847 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0146 | 0.00000000841 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0024 | 0.3847 | 0.5 |
Treponema pallidum | ATP-dependent DNA helicase | 0.0012 | 0.0146 | 0.5 |
Plasmodium falciparum | ADP-dependent DNA helicase RecQ | 0.0024 | 0.3847 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 0.3847 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1). (Class of assay: confirmatory) [Related pubchem assays: 594 (Rhodamine region spectral profiling screen), 593 (Fluorescein region spectral profiling screen), 2367 (Probe Development Summary for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)), 2353 (qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1))] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.